Document is current
Any future updates will be listed below
-
Authors
Brisset, Morgan
Grandin, Mélodie https://orcid.org/0000-0001-6784-9496
Bernet, Agnès
Mehlen, Patrick https://orcid.org/0000-0003-1743-5417
Hollande, Frédéric https://orcid.org/0000-0002-7046-8392
-
Funding
Funding for this research was provided by:
INSERM/University of Melbourne (LIA2018)
CNRS/University of Melbourne (MCN2020)
Department of Health, Australian Government|National Health and Medical Research Council (1164081)
John Landerer
- License Information
-
More Information
Article History
Received: 30 April 2021
Revised: 11 August 2021
Accepted: 11 August 2021
First Online: 20 September 2021
Conflict of interest
: Patrick Mehlen and Agnès Bernet are shareholders of Netris Pharma, which develops a netrin‐1 antibody for clinical use. The other authors declare no conflict of interest.
